Alport syndrome is a rare inherited disease characterized by progressive renal failure, hearing loss, and ocular abnormalities.\[[@ref1]\] It is caused by mutations in type IV collagen. The progressive damage to the basement membrane containing mutated form of type 4 collagen leads to microscopic hematuria, sensorineural deafness, anterior lenticonus, and progressive kidney dysfunction leading to end-stage renal disease.\[[@ref1]\]

Case {#sec1-2}
====

A 26-year-old female was referred to our institute with a history of gradual, painless progressive diminution of vision in both eyes since 1 year. The best-corrected visual acuity was 6/60 (−12D Sph/−1D Cyl 20°) in right eye and 6/18 (−8D Sph/−0.50D Cyl 180°) in left eye. Slit-lamp examination in the right eye revealed a clear lens with anterior lenticonus \[[Fig. 1a](#F1){ref-type="fig"}\] and posterior lenticonus \[[Fig. 1b](#F1){ref-type="fig"}\]. Retinoscopy revealed a central oil droplet reflex \[[Fig. 1c](#F1){ref-type="fig"}\]. Slit-lamp examination of the left eye revealed anterior capsular opacity \[[Fig. 2a](#F2){ref-type="fig"}\]. She also gave history of progressive hearing loss. Fundus examination showed grade 4 hypertensive retinopathy in both eyes \[Figs. [1d](#F1){ref-type="fig"} and [2b](#F2){ref-type="fig"}\]. Anterior segment ocular coherence tomography (OCT) of the right eye showed a conical protrusion of the anterior lens capsule \[[Fig. 3a](#F3){ref-type="fig"}\] and left eye showed a hyperreflective opacity on the anterior capsule suggestive of a break and fibrosis of the capsule \[[Fig. 3b](#F3){ref-type="fig"}\]. Retinal OCT showed intraretinal hard exudates in both eyes and no change in central macular thickness \[Fig. [4a](#F4){ref-type="fig"} and [b](#F4){ref-type="fig"}\].

![(a) Right eye slit section showing anterior lenticonus, (b) right eye slit section showing posterior lenticonus, (c) right eye anterior segment photograph showing oil droplet reflex, and (d) right eye fundus picture showing mild optic disc edema, severe arteriolar attenuation, increased arteriovenous crossing changes, and multiple intraretinal hard exudates around the macula](IJO-66-1319-g001){#F1}

![(a) Left eye anterior segment photographs showing anterior capsular opacity and (b) left eye fundus picture showing mild optic disc edema, severe arteriolar attenuation, increased arteriovenous crossing changes, and multiple intraretinal hard exudates around the macula](IJO-66-1319-g002){#F2}

![(a) Right eye anterior segment optical coherence tomography showing conical protrusion in the anterior lens capsule and (b) left eye anterior segment optical coherence tomography showing hyperreflective anterior capsular opacity](IJO-66-1319-g003){#F3}

![(a) Right eye macular optical coherence tomography scan showing intraretinal hard exudates and (b) left eye macular optical coherence tomography scan showing intraretinal hard exudates](IJO-66-1319-g004){#F4}

Discussion {#sec1-3}
==========

Alport syndrome is an inherited disease characterized by progressive renal failure, hearing loss, and ocular abnormalities.\[[@ref1]\] Mutations in *COL4A5* (X-linked), or *COL4A3* and *COL4A4* (autosomal recessive) genes result in the absence of collagen IV α3α4α5 network from the basement membranes of the cornea, lens capsule, and retina and are associated with corneal opacities, anterior lenticonus, fleck retinopathy, and temporal retinal thinning.\[[@ref2]\] The demonstration of lenticonus is diagnostic for Alport syndrome.\[[@ref3]\] The anterior lenticonus was not clearly evident in the left eye due to rupture of the anterior capsule resulting in fibrosis of the capsule. Posterior lenticonus also occurs but is less common.\[[@ref4]\]
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